FDA issued a Warning Letter to BioReliance Corporation on 1/5/2009 for a previous inspection.
483 BioReliance Jul 2018

483 BioReliance Jul 2018

Susan Jackson FDA$119.00 - Available Now

FDA investigators audited the BioReliance - Rockville, MD, United States facility and issued inspectional observations (via FDA 483) on 13 Jul 2018.

Product details

  • Category: Biologics / Human Drugs
  • Inspection end: 13 Jul 2018
  • Location: Rockville, United States
  • FEI: 1122041
Add To Cart